SLGL supply chain intelligence for Sol-Gel Technologies Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Sol-Gel Technologies Ltd. (SLGL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ROYALTY-SECURITY-LLC | ROYALTY-SECURITY-LLC | 90% | In January 2023, we purchased assets related to our SGT-610 product candidate, which included certain intellectual property rights owned by PellePharm Inc., or PellePharm, and licensed to PellePharm … |
| ACRS | Aclaris Therapeutics, Inc. | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted … |
| BHC | Bausch Health Companies Inc. | 72% | ay ® product candidate (one patent family has granted patents in Canada, India, Mexico, Europe and Japan (with a term until 2028) and a pending application in the United States; and the second patent… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from BHC graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from BHC grap… |
| NVSEF | Novartis AG | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSE… |
| ORANY | ORANY | 72% | with third parties that have sales and marketing experience. We intend to commercialize our late-stage branded product candidates in the United States, if approved, by building a specialized sales an… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from SLGL graph: with third parties that have sales and marketing experience. We intend to commercialize our late-stage branded produ… |
| PRGO | Perrigo Company plc | 72% | Reciprocal relationship from PRGO graph: Reciprocal relationship from SLGL graph: in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted … |
| PRGO | Perrigo Company plc | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| VYNE | VYNE Therapeutics Inc. | 72% | clinical site initiation and recruiting clinical site investigators and clinical site staff; • increased rates of patients withdrawing from our clinical trials following enrollment as a result of con… |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from SLGL graph: clinical site initiation and recrui… |
| SLE | Super League Enterprise, Inc. | 62% | Reciprocal relationship from SLE graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from SLE graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from SLE grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PADAGIS-ISRAEL-PHARMACEUTICALS-LTD | PADAGIS-ISRAEL-PHARMACEUTICALS-LTD | 85% | NOTE 8 — COLLABORATION AGREEMENTS: a. In 2007, the Company sublicensed rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is ent… |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SLGL graph: in Mexico (with a term until 2029) … |
| ACRS | Aclaris Therapeutics, Inc. | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| BHC | Bausch Health Companies Inc. | 72% | ay ® product candidate (one patent family has granted patents in Canada, India, Mexico, Europe and Japan (with a term until 2028) and a pending application in the United States; and the second patent… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from BHC graph: Reciprocal relationship from SLGL graph: ay ® product candidate (one patent fa… |
| NVSEF | Novartis AG | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSE… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from ORAN… |
| ORANY | ORANY | 72% | with third parties that have sales and marketing experience. We intend to commercialize our late-stage branded product candidates in the United States, if approved, by building a specialized sales an… |
| PRGO | Perrigo Company plc | 72% | Reciprocal relationship from PRGO graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from PRGO graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from PRGO g… |
| PRGO | Perrigo Company plc | 72% | in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, Unite… |
| VYNE | VYNE Therapeutics Inc. | 72% | Reciprocal relationship from VYNE graph: Reciprocal relationship from SLGL graph: ndividual states in the United States have also become increasingly active in passing legislation and implementing re… |
| VYNE | VYNE Therapeutics Inc. | 72% | ndividual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or p… |
| MEDICIS-PHARMACEUTICAL-CORPORATION | MEDICIS-PHARMACEUTICAL-CORPORATION | 62% | ormation to support our research, development and other activities. Our failure to comply with the data privacy and security principles set forth in HIPAA, or a breach of health information or person… |
| MPC | Marathon Petroleum Corporation | 62% | Reciprocal relationship from MPC graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from MPC graph: Reciprocal relationship from SLGL graph: ormation to support our research, dev… |
| SEARCHLIGHT-PHARMA-INC | SEARCHLIGHT-PHARMA-INC | 62% | . The Company has identified one performance obligation in the Termination Agreement. Revenue from sale of IP is recognized at a point in time, upon transfer of control over the sale of the IP to Pad… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SLGL-DEBT | Debt stack $65.3M | 90% | Market cache reports total debt of $65.3M. |
| SLGL-DEBT-12584 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| SLGL-DEBT-12583 | Warrants outstanding: 54144 | 90% | xbrl warrant detail from xbrl 2017-07-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SLGL-OWNER-OPALEYE-MANAGEMENT-INC | Opaleye Management Inc. | 90% | 13F overlay lists Opaleye Management Inc. as top holder; 20 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| HLNCF | Haleon plc | 100.00 | 2 | |
| KLRS | Kalaris Therapeutics, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 | |
| HLN | Haleon plc | 100.00 | 2 | |
| JBIO | Jade Biosciences, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| ACRS | Aclaris Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| BHC | Bausch Health Companies Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| LQDA | Liquidia Corporation | 100.00 | 2 |